Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other Accumulated Expenses: 2022

Historic Other Accumulated Expenses for InMed Pharmaceuticals (INM) over the last 1 years, with Jun 2022 value amounting to $3.2 million.

  • InMed Pharmaceuticals' Other Accumulated Expenses was N/A to $2.3 million in Q1 2023 from the same period last year, while for Mar 2023 it was $2.3 million, marking a year-over-year change of. This contributed to the annual value of $3.2 million for FY2022, which is N/A change from last year.
  • InMed Pharmaceuticals' Other Accumulated Expenses amounted to $3.2 million in FY2022.
  • InMed Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $3.2 million for FY2022, and its period low was $3.2 million during FY2022.
  • In the last 1 years, InMed Pharmaceuticals' Other Accumulated Expenses had a median value of $3.2 million in 2022 and averaged $3.2 million.